CEL-SCI Reported New Data From Its Concluded Phase 3 Study Of Multikine (Leukocyte Interleukin, Injection) Presented At The European Society For Medical Oncology, Showing An Increased 5-year Survival Rate To 82.6% In Locally Advanced Resectable Head & Neck Cancer Patients
Portfolio Pulse from Benzinga Newsdesk
CEL-SCI presented new data from its Phase 3 study of Multikine, showing a 5-year survival rate of 82.6% in certain head and neck cancer patients. This marks the strongest efficacy results for Multikine, suggesting improved outcomes with better patient selection.
September 16, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CEL-SCI's Multikine demonstrated a significant increase in 5-year survival rates for head and neck cancer patients, suggesting strong efficacy and potential for improved outcomes with better patient selection in future studies.
The new data from CEL-SCI's Phase 3 study of Multikine shows a significant improvement in survival rates, which is a positive indicator for the company's future prospects. The results suggest that with better patient selection, the efficacy of Multikine could be further enhanced, potentially leading to increased adoption and regulatory approval. This news is likely to positively impact CEL-SCI's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100